Clinical Trials · NCT06982846
A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 80
- Start date
- Jun 2025
- Locations
- 1 site, Austria
- Primary endpoint
- Time-to-Event of Recovery of Plasma Glucose (PG) Concentration from 48 Milligram per Deciliter (48 mg/dL) to 70 mg/dL (tPG_nadir-70 mg/dL)